PHARMACOL RES 润色咨询

PHARMACOLOGICAL RESEARCH

出版年份:1989 年文章数:3070 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:3.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2022-12-04 1241217bm20暂无昵称 来自江苏省

    这周刚接受了一篇,速度很快,很爽!!

    8

    展开8条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2023-09-22 ms6000002095545543 来自河南省

    想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2022-09-08 待我慢慢

    审稿速度:2.0
    偏重的研究方向:单体;综述
    经验分享:7.4 投稿
    7.5 拒稿,建议修改标题,并补充
    7.12 修改后Submitted to Journal
    7.12 With Editor
    7.12 Under Review
    8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见
    8.12 晚上 Major Revise (20天期限)
    8.30 With Editor
    9.1 Under Review
    9.3 两个审稿人意见返回
    9.3 Decision in Process
    9.8 Accept
    投稿后拒稿在次投稿,希望可以给大家参考一下。

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2023-11-30 周大-Jagger 来自天津

    请问这个投稿后,必须要每个作者邮件确认么?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2023-06-22 少吃一口 来自四川省

    偏重的研究方向:靶向治疗;药理;综述
    经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?

    6

    展开6条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2023-01-02 ms9000001669050818

    投稿命中率:50.0
    偏重的研究方向:机制;药效;疗效
    经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2022-02-07 148b3499m91暂无昵称

    required reviews completed已经一周了,请问有类似情况的吗?

    6

    展开6条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2020-10-26 Charlo

    10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。

    14

    展开14条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2023-11-13 ms2000000030700368 来自贵州省

    这个投稿,必须要每个作者确认么

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇,速度很快,很爽!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0<br>偏重的研究方向:单体;综述<br>经验分享:7.4 投稿<br>7.5 拒稿,建议修改标题,并补充<br>7.12 修改后Submitted to Journal<br>7.12 With Editor<br>7.12 Under Review<br>8.12 三个审稿人意见返回,Required Reviews Completed,最后回了三个意见<br>8.12 晚上 Major Revise (20天期限)<br>8.30 With Editor<br>9.1 Under Review<br>9.3 两个审稿人意见返回<br>9.3 Decision in Process<br>9.8 Accept<br>投稿后拒稿在次投稿,希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后,必须要每个作者邮件确认么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向:靶向治疗;药理;综述<br>经验分享:6月21号晚上投稿,综述看下什么情况,能中的话会回来评论 另外想问下各位投稿稿件号都到多少了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0<br>偏重的研究方向:机制;药效;疗效<br>经验分享:required reviews completed状态持续5天了,好久了,是因为过元旦吗,有没有类似情况的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了,请问有类似情况的吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交,10.26号接收,神速啊,感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿,必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向:免疫<br>经验分享:9.12 Submitted to Journal<br>9.12 2小时后 With Editor<br>然后,没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古)]
    2023-09-18 1487e742m42(暂无昵称) 来自内蒙古

    偏重的研究方向:免疫
    经验分享:9.12 Submitted to Journal
    9.12 2小时后 With Editor
    然后,没有动静了。。。

    4

    展开4条回复
共500条页码: 2/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分